{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:03:27Z","timestamp":1762430607896},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T00:00:00Z","timestamp":1327104000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00228-012-1213-x","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T11:39:03Z","timestamp":1327059543000},"page":"903-912","source":"Crossref","is-referenced-by-count":24,"title":["The adverse event profile of pregabalin across different disorders: a meta-analysis"],"prefix":"10.1007","volume":"68","author":[{"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Franco","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,21]]},"reference":[{"key":"1213_CR1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","volume":"38","author":"AG Marson","year":"1997","unstructured":"Marson AG, Kadir ZA, Hutton JL, Chadwick DW (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38:859\u2013880","journal-title":"Epilepsia"},{"key":"1213_CR2","unstructured":"Marson AG, Kadir ZA, Hutton JL, Chadwick DW (2000) Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev (2): CD001415. Update in: Cochran Database Syst Rev 2000;3: CD001415"},{"key":"1213_CR3","unstructured":"Chadwick DW, Marson AG (2000) Zonisamide for drug-resistant partial epilepsy. Cochrane Database Syst Rev (2):CD001416. Update in: Cochrane Database Syst Rev 2002;2:CD001416"},{"key":"1213_CR4","unstructured":"Jette NJ, Marson AG, Kadir ZA, Hutton JL (2000) Topiramate for drugresistant partial epilepsy. Cochrane Database Syst Rev (2):CD001417. Update in: Cochran Database Syst Rev 2002;3:CD001417"},{"key":"1213_CR5","doi-asserted-by":"crossref","unstructured":"Ramaratnam S, Marson AG, Baker GA (2001) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000; (3):CD001909. Update in: Cochrane Database Syst Rev 3:CD001909","DOI":"10.1002\/14651858.CD001909"},{"key":"1213_CR6","doi-asserted-by":"crossref","unstructured":"Chaisewikul R, Privitera MD, Hutton JL, Marson AG (2001) Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev (1):CD001901","DOI":"10.1002\/14651858.CD001901"},{"key":"1213_CR7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0920-1211(01)00287-X","volume":"46","author":"AG Marson","year":"2001","unstructured":"Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, Chaisewikul R, Privitera M, Chadwick DW (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46:259\u2013270","journal-title":"Epilepsy Res"},{"key":"1213_CR8","unstructured":"Chadwick DW, Marson AG (2002) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (4):CD001416. Update in: Cochran Database Syst Rev 2005;4:CD001416."},{"key":"1213_CR9","first-page":"CD001900","volume":"4","author":"JP Leach","year":"2002","unstructured":"Leach JP, Marson AG, Hutton JL (2002) Remacemide for drug-resistant localization related epilepsy. Cochrane Database Syst Rev 4:CD001900","journal-title":"Cochrane Database Syst Rev"},{"key":"1213_CR10","doi-asserted-by":"crossref","unstructured":"Pereira J, Marson AG, Hutton JL (2002) Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3):CD001908","DOI":"10.1002\/14651858.CD001908"},{"key":"1213_CR11","unstructured":"Chadwick DW, Marson AG (2005) Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (4):CD001416"},{"key":"1213_CR12","doi-asserted-by":"crossref","unstructured":"Hemming K, Maguire MJ, Hutton JL, Marson AG (2008) Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 2008; (3):CD007302","DOI":"10.1002\/14651858.CD007302"},{"key":"1213_CR13","doi-asserted-by":"crossref","unstructured":"Jette N, Hemming K, Hutton JL, Marson AG (2008) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev (3):CD001417","DOI":"10.1002\/14651858.CD001417.pub2"},{"key":"1213_CR14","unstructured":"Lozsadi D, Hemming K, Marson AG (2008) Pregabalin add-on for drug resistant partial epilepsy. Cochrane Database Syst Rev (1):CD005612"},{"key":"1213_CR15","doi-asserted-by":"crossref","unstructured":"Michael B, Marson AG (2008) Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev (2):CD004154","DOI":"10.1002\/14651858.CD004154.pub4"},{"key":"1213_CR16","doi-asserted-by":"crossref","unstructured":"Zaccara G, Gangemi PF, Perucca P, Specchio L (2011) The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia (in print). doi: 10.1111\/j.1528-1167.2010.02966.x","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"1213_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557\u2013560","journal-title":"Br Med J"},{"key":"1213_CR18","unstructured":"RevMan (2008) Review Manager (RevMan) [computer program]. Version 5.1. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen"},{"key":"1213_CR19","first-page":"13","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"1981","unstructured":"Fleiss JL (1981) Statistical methods for rates and proportions. Wiley, New York, pp 13\u201317"},{"issue":"1","key":"1213_CR20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","volume":"45","author":"S Arroyo","year":"2004","unstructured":"Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S (2004) Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45(1):20\u201327","journal-title":"Epilepsia"},{"key":"1213_CR21","doi-asserted-by":"crossref","unstructured":"Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, Pregabalin 1008-009 Study Group (2005) Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64(3):475\u2013480","DOI":"10.1212\/01.WNL.0000150932.48688.BE"},{"issue":"12","key":"1213_CR22","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","volume":"46","author":"CE Elger","year":"2005","unstructured":"Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA (2005) Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46(12):1926\u20131936","journal-title":"Epilepsia"},{"key":"1213_CR23","doi-asserted-by":"crossref","unstructured":"French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA (2003) Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60(10):1631\u20131637","DOI":"10.1212\/01.WNL.0000068024.20285.65"},{"issue":"3","key":"1213_CR24","first-page":"240","volume":"23","author":"DE Feltner","year":"2003","unstructured":"Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23(3):240\u2013249","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1213_CR25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","volume":"67","author":"SA Montgomery","year":"2006","unstructured":"Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67(5):771\u2013782","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1213_CR26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","volume":"160","author":"AC Pande","year":"2003","unstructured":"Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160(3):533\u2013540","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1213_CR27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","volume":"24","author":"AC Pande","year":"2004","unstructured":"Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24(2):141\u2013149","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"1213_CR28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","volume":"62","author":"K Rickels","year":"2005","unstructured":"Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62(9):1022\u20131030","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"1213_CR29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9(9):792\u2013805","journal-title":"J Pain"},{"issue":"3","key":"1213_CR30","first-page":"502","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35(3):502\u2013514","journal-title":"J Rheumatol"},{"key":"1213_CR31","unstructured":"Anonymous (2008) A 14 week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia. Protocol no. A0081100, clinical study synopsis"},{"issue":"8","key":"1213_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-8-33","volume":"16","author":"JC Arezzo","year":"2008","unstructured":"Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L (2008) Efficacy and safety of pregabalin 600\u00a0mg\/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 16(8):33","journal-title":"BMC Neurol"},{"key":"1213_CR33","doi-asserted-by":"crossref","unstructured":"Lesser H, Sharma U, LaMoreaux L, Poole RM (2004 ) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63(11):2104\u20132110","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"issue":"4","key":"1213_CR34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"RW Richter","year":"2005","unstructured":"Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6(4):253\u2013260","journal-title":"J Pain"},{"issue":"2","key":"1213_CR35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","volume":"12","author":"T T\u00f6lle","year":"2008","unstructured":"T\u00f6lle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr (2008) Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 12(2):203\u2013213","journal-title":"Eur J Pain"},{"key":"1213_CR36","unstructured":"Anonymous (2007) A placebo-controlled trial of pregabalin and amitriptyline for treatment of painful diabetic peripheral neuropathy. Protocol no. 1008-040, PhRMA clinical study dynopsis"},{"key":"1213_CR37","unstructured":"Anonymous (2007) A randomized, double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Protocol no. A0081071, clinical study synopsis"},{"issue":"3","key":"1213_CR38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115(3):254\u2013263","journal-title":"Pain"},{"key":"1213_CR39","unstructured":"Anonymous (2009) A 13-week, randomized, double-blind, multicenter, placebo-controlled study toevaluate efficacy and safety of pregabalin (CI-1008) in the treatment of postherpetic neuralgia. Protocol no. A0081120, clinical study synopsis"},{"key":"1213_CR40","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM (2003) Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60(8):1274\u20131283","DOI":"10.1212\/01.WNL.0000055433.55136.55"},{"issue":"2","key":"1213_CR41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1185\/030079906X80404","volume":"22","author":"R Seventer van","year":"2006","unstructured":"van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L (2006) Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 22(2):375\u2013384","journal-title":"Curr Med Res Opin"},{"key":"1213_CR42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0025-6196(11)60965-8","volume":"82","author":"JI Sirven","year":"2007","unstructured":"Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF (2007) Second-generation antiepileptic drugs' impact on balance: a meta-analysis. Mayo Clin Proc 82:40\u201347","journal-title":"Mayo Clin Proc"},{"key":"1213_CR43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1528-1157.1980.tb04081.x","volume":"21","author":"RJ Hoppener","year":"1980","unstructured":"Hoppener RJ, Kuyer A, Meijer JWA, Hulsman J (1980) Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 21:341\u2013350","journal-title":"Epilepsia"},{"key":"1213_CR44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","volume":"6","author":"G Zaccara","year":"2004","unstructured":"Zaccara G, Cincotta M, Borgheresi A, Balestrieri F (2004) Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 6:153\u2013168","journal-title":"Epileptic Disord"},{"issue":"Suppl 1","key":"1213_CR45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1528-1167.2010.02905.x","volume":"52","author":"AT Berg","year":"2011","unstructured":"Berg AT (2011) Epilepsy, cognition, and behavior: the clinical picture. Epilepsia 52(Suppl 1):7\u201312","journal-title":"Epilepsia"},{"issue":"Suppl 9","key":"1213_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1528-1167.2007.01400.x","volume":"48","author":"BA Malow","year":"2007","unstructured":"Malow BA (2007) The interaction between sleep and epilepsy. Epilepsia 48(Suppl 9):36\u201338","journal-title":"Epilepsia"},{"key":"1213_CR47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jad.2007.03.005","volume":"104","author":"T Ietsugu","year":"2007","unstructured":"Ietsugu T, Sukigara M, Furukawa TA (2007) Evaluation of diagnostic criteria for panic attack using item response theory: findings from the National Comorbidity Survey in USA. J Affect Disord 104:197\u2013201","journal-title":"J Affect Disord"},{"key":"1213_CR48","first-page":"166","volume":"18","author":"F Civeira","year":"1970","unstructured":"Civeira F, Basallo F (1970) The diabetic heart. Diabete 18:166\u2013170","journal-title":"Diabete"},{"key":"1213_CR49","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","volume":"287","author":"AJ Barsky","year":"2002","unstructured":"Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622\u2013627","journal-title":"JAMA."},{"key":"1213_CR50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","volume":"59","author":"P Enck","year":"2008","unstructured":"Enck P, Benedetti F, Schedlowski M (2008) New insights into the placebo and nocebo responses. Neuron 59:195\u2013206","journal-title":"Neuron"},{"key":"1213_CR51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pain.2009.07.010","volume":"146","author":"M Amanzio","year":"2009","unstructured":"Amanzio M, Corazzini LL, Vase L, Benedetti F (2009) A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146:261\u2013269","journal-title":"Pain"},{"key":"1213_CR52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1352458510370793","volume":"16","author":"D Papadopoulos","year":"2010","unstructured":"Papadopoulos D, Mitsikostas DD (2010) Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 16:816\u2013828","journal-title":"Mult Scler"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-012-1213-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1213-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T03:08:32Z","timestamp":1713409712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-012-1213-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,21]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s00228-012-1213-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,21]]}}}